GLP-1 medications are best known for diabetes and weight management, but dermatologists are also studying their relationship with inflammation and conditions such as psoriasis.

GLP-1 medications have received enormous attention over the past few years, primarily because of their use in diabetes and weight management. But dermatologists are paying attention for another reason.

We are learning more about the relationship between metabolic health, chronic inflammation and inflammatory skin conditions such as psoriasis. That has raised an interesting question: could some patients taking GLP-1 medications experience changes in their skin disease as their weight and metabolic health improve?

The answer is not as simple as saying GLP-1 medications treat psoriasis. They do not. These medications are not FDA-approved to treat psoriasis or other skin diseases, and the research in dermatology is still developing.

What we are learning, however, gives us another reason to look at psoriasis as more than something happening on the surface of the skin.

What Does Weight Have to Do With Your Skin?

This is where the conversation gets interesting.

We used to think of body fat largely as stored energy. We now understand that adipose tissue is biologically active. It releases signaling proteins called cytokines, some of which contribute to inflammation throughout the body.

For patients living with obesity, that can mean a persistent state of low-grade inflammation.

The skin is not separate from what is happening elsewhere in the body. Chronic inflammatory skin diseases are influenced by the immune system, which means changes in systemic inflammation can matter to what we see on the skin.

This connection is particularly well established in psoriasis.

Metabolic health and skin health are connected. Excess adipose tissue can contribute to inflammatory signals throughout the body.

Psoriasis Is More Than a Skin Condition

Psoriasis may be visible on the skin, but it is an immune-mediated inflammatory disease.

People with psoriasis also have higher rates of several health conditions, including obesity, diabetes and cardiovascular risk factors. Research has found a relationship between higher body mass index and both the risk and severity of psoriasis.

That does not mean someone's weight "caused" their psoriasis. Psoriasis is a complex disease influenced by genetics, the immune system, environmental factors and other aspects of health.

It does mean that weight and metabolic health can become part of the larger conversation when we are trying to manage psoriasis well.

For some patients, reducing excess weight may also reduce some of the inflammatory signals associated with adipose tissue. Studies have found that weight loss can improve psoriasis severity in certain patients, although it does not happen for everyone.

So Where Do GLP-1 Medications Fit In?

GLP-1 medications mimic hormones involved in blood sugar regulation, appetite and digestion. They have become important tools for treating type 2 diabetes and obesity.

The dermatology connection is newer.

One reason researchers are interested in GLP-1 medications is fairly straightforward. If a patient loses a meaningful amount of excess weight, the amount of inflammation associated with adipose tissue may decrease.

But there may be more happening.

Early research suggests GLP-1 medications may have anti-inflammatory and immunologic effects that extend beyond weight loss alone. GLP-1 receptors have been identified on certain immune cells involved in regulating inflammation.

That does not mean we can currently prescribe a GLP-1 medication as a standard treatment for psoriasis. It does tell us there is a biological reason researchers are interested in studying the relationship.

And that distinction matters.

Researchers are investigating whether GLP-1 medications may influence inflammatory skin disease through weight loss, metabolic improvements and possible anti-inflammatory effects.

What Are We Seeing With Psoriasis?

This is probably the most interesting part for patients.

The American Academy of Dermatology article I reviewed discusses reports of patients with psoriasis who experienced improvement as they lost weight while taking GLP-1 medications. It also points to small clinical trials and analyses that have reported improvements in psoriasis severity and quality of life with certain GLP-1 medications.

There are also studies underway looking more directly at GLP-1 medications alongside established psoriasis therapies.

That is encouraging, but we need to keep it in perspective.

Much of the dermatology-specific research is still small, early or observational. We do not yet have enough evidence to say that GLP-1 medications should become routine psoriasis treatments.

For now, I see this as part of a bigger shift in how we think about inflammatory skin disease. Treating the skin remains important, but sometimes we also need to look beyond the skin.

The Skin Can Tell Us Something About Overall Health

One of the reasons I find this research important is that dermatology gives us a unique window into what may be happening elsewhere in the body.

When I see a patient with psoriasis in my Atlanta office, my concern is not limited to plaques, itching or clearing the visible skin. Psoriasis can be associated with other health issues, and those deserve attention too.

For a patient who also has obesity, diabetes, high blood pressure or other metabolic concerns, it may make sense for their dermatologist, primary care physician and other specialists to work together.

A GLP-1 medication may already be appropriate for that patient because of an FDA-approved indication such as diabetes or obesity. If their psoriasis improves as their metabolic health improves, that becomes useful information for all of us caring for that patient.

That is very different from prescribing the medication solely because someone has psoriasis.

Dr. Elise Barnett takes a whole-patient approach to psoriasis care, considering both the skin and health factors that may contribute to inflammation.

What If I'm Already Taking a GLP-1 Medication?

Tell your dermatologist.

Not because you necessarily need to change anything, but because medications, weight changes, nutrition and other health changes are all relevant to your skin.

Rapid weight loss can sometimes have unwanted effects that dermatologists see, including temporary hair shedding. Changes in facial volume can also become noticeable after significant weight loss.

If you have psoriasis or another inflammatory skin condition, let us know if you notice improvement, worsening or a change in your usual symptoms after starting a new medication.

That information can help us understand the whole picture.

What This Research Means for My Atlanta Psoriasis Patients

For me, the most useful takeaway is not that we have discovered a new psoriasis drug.

We haven't.

It is that our understanding of psoriasis continues to expand.

The immune system, metabolic health, body weight and skin inflammation do not exist in separate boxes. For some patients, addressing one part of their health may influence another.

That is why I think dermatology works best when we look at the patient in front of us rather than treating an isolated patch of skin.

If you have psoriasis and are also dealing with weight or metabolic health concerns, that is a conversation worth having with your physicians. And if you are already using a GLP-1 medication and have noticed changes in your psoriasis, hair or skin, tell your dermatologist.

We may learn something useful from it.

Frequently Asked Questions

This post is for informational purposes only and does not constitute medical advice. GLP-1 medications are not FDA-approved for the treatment of psoriasis or other dermatologic diseases. Do not start, stop or change a prescription medication without discussing it with the physician managing your care.

Source: "The Role of GLP-1s in Dermatology," Dermatology World, American Academy of Dermatology, January 2026.